Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition.

A trend in favor of metformin was observed after summarizing all microvascular endpoints, but it did not reach statistical significance. 12 However, a retrospective analysis of a Veterans Administration database including 93,577 T2D patients revealed that treatment with sulfonylureas (n = 30,550) resulted in a 20% higher incidence of a composite of persistent reduction of eGFR of >25% from baseline, ESKD, and/or death from renal cause in comparison to treatment with metformin (n = 60,104) or rosiglitazone (n = 1,923). 19 An overview on the results of this study, and a comparison to the studies presented subsequently, are provided in Table 1 .

also in 111,027 other papers